Advertisement

NCI BSA approves nine new and reissued concepts

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The NCI Board of Scientific Advisors approved nine new and reissued concepts at a meeting held March 28-29.

Also at the meeting, NCI Director Ned Sharpless—who recently announced that he would step down April 29—discussed the state of FY22 funding and President Joe Biden’s reinvigorated Moonshot (The Cancer Letter, Apr. 1, Apr. 4, 2022). 

Douglas Lowy, principal deputy director of NCI, delivered a presentation on how the FY22 NCI budget will affect research project grant paylines (The Cancer Letter, Apr. 1, 2022). Paylines for R01 grants for new and established investigators will stay at the 11th percentile, complicating NCI’s goal of reaching the 15th percentile by 2025. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Alice Tracey
Alice Tracey
Reporter
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
Advertisement
Advertisement